Caricamento...
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...
Salvato in:
| Pubblicato in: | Cardiovasc Diabetol |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5598064/ https://ncbi.nlm.nih.gov/pubmed/28903775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0595-6 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|